Sharechat Logo

Rua Bioscience Limited (NZX: RUA) Announces CCO with Global Pharma Experience

Monday 19th April 2021

Text too small?

Rua Bioscience Ltd has appointed experienced global pharmaceutical executive Dr Andrea Grant as Chief Commercial Officer (CCO). Dr Grant will drive the medicinal cannabis company’s domestic and global commercialisation and business development strategy. Dr Grant's first priority will be to lead Rua's global expansion into key markets.

She brings 20 years of business development experience in the pharmaceutical and biotech industries globally. Dr Grant comes to Rua from Janssen Cilag Pty NZ (the pharmaceutical business of Johnson & Johnson), where she was the Market Access Manager responsible for commercialising innovative medicines to NZ patients.

Her global experience in biotech includes senior business development roles at Incyte and Galapagos, both during their early stages of transitioning to fully integrated pharmaceutical companies, as well as Management Director of Living Cell Technologies. Dr Grant will also add value to Rua’s global commercial discipline, her experience garnered from working with pharmaceutical stalwarts like Janssen and Roche.

Rua Bioscience CEO Rob Mitchell says, “Andi is an exciting hire for the company as we prepare to enter both the German and domestic markets and develop our IP strategy across the medicinal cannabis value chain.”

The first market is Germany, where Rua holds an exclusive distribution agreement with Nimbus Health. In a recent report authored by global researchers Prohibition Partners, it is estimated Germany’s medicinal cannabis market will be worth over €840 million (NZ$1.4 billion) by the end of 2024. Plans for this market are well-advanced, and Rua hopes to be in a position to supply high quality, GMP grade flower to Germany under its distribution agreement with Nimbus by year's end.

"Andi has carved out an outstanding international career focused on the commercialisation of medical innovations in the pharmaceutical and biotech sectors across the UK, Europe, USA, NZ and Asia.

"She's a proven value creator, skilled negotiator and vastly experienced leader who knows how to bring novel products to market. She is also a great fit for Rua’s unique vision and kaupapa," he says.

Please see the link below for details:

Rua Bioscience announces CCO with global pharmaceutical and biotech experience

Source: Rua Bioscience Limited



  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

Pacific Edge Limited (NZX: PEB) Placement Upsized Following Strong Demand
24th September 2021 Morning Report
23rd September 2021 Morning Report
Pacific Edge Limited (NZX: PEB) Dual Lists on ASX; Announces Capital Raise to Accelerate
Tower Limited (NZX: TWR) Updates Guidance
South Port New Zealand Limited (NZX: SPN) 2021 Annual Report
22nd September 2021 Morning Report
Kathmandu Holdings Limited (NZX: KMD) FY21 Annual Results Announcement
Stride Property Ltd & Stride Investment Management Ltd (NZX: SPG) Update on Demerger and Office Fund
21st September 2021 Morning Report